Therapy

Palladium 103 Brachytherapy in Adenocarcinoma of the Prostate

Published in Cancer Weekly, July 27th, 1998

Palladium 103 (Pd-103) brachytherapy in Stage T1 and T2 adenocarcinoma of the prostate proved effective in reducing PSA levels to less than 1.5 ng/mL and in producing negative biopsies one and two years postoperatively in a recent study.

J. Sharkey et al. sought to assess the effectiveness of palladium 103 brachytherapy in Stage T1 and T2 adenocarcinoma of the prostate ("Outpatient Ultrasound-Guided Palladium 103 Brachytherapy for Localized Adenocarcinoma of the Prostate: A Preliminary Report of 434 Patients," Urology, May 1998;51(5):796-803).

"Charts of four hundred seventy four patients treated between 1991 and 1996 with transperineal real-time...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-07-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry